MCP-1, not MIP-1alpha, is the endogenous chemokine that cooperates with TGF-beta to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures - PubMed (original) (raw)
Comparative Study
. 1998 Oct 1;92(7):2338-44.
Affiliations
- PMID: 9746772
Free article
Comparative Study
MCP-1, not MIP-1alpha, is the endogenous chemokine that cooperates with TGF-beta to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures
J D Cashman et al. Blood. 1998.
Free article
Abstract
The long-term culture (LTC) system has been useful for analyzing mechanisms by which stromal cells regulate the proliferative activity of primitive normal, but not chronic myeloid leukemia (CML), hematopoietic progenitor cells. In previous studies, we identified two endogenous inhibitors in this system. One is transforming growth factor-beta (TGF-beta), which is equally active on primitive normal and CML progenitors. The other we now show to be monocyte chemoattractant protein-1 (MCP-1). Thus, MCP-1, when added to LTC, blocked the activation of primitive normal progenitors but did not arrest the cycling of primitive CML progenitors. Moreover, the endogenous inhibitory activity of LTC stromal layers could be overcome by the addition of neutralizing antibodies to MCP-1, but not to macrophage inflammatory protein-1alpha (MIP-1alpha). However, neither of these antibodies antagonized the inhibitory activity of NAc-Ser-Asp-Lys-Pro (AcSDKP) on primitive normal but not CML progenitor cycling in this system. Moreover, none of six other -C-C- or -C-X-C- chemokines, previously shown to inhibit primitive normal human CFC proliferation in semisolid assays, were found to act as negative regulators when added to normal LTC. These results provide further support for the concept that primitive CML progenitor cell proliferation is deregulated when these cells are exposed to limiting concentrations of multiple inhibitors, only some of which have differential actions on normal and Ph+/BCR-ABL+ cells.
Similar articles
- The biology of normal and neoplastic stem cells in CML.
Eaves C, Udomsakdi C, Cashman J, Barnett M, Eaves A. Eaves C, et al. Leuk Lymphoma. 1993;11 Suppl 1:245-53. doi: 10.3109/10428199309047894. Leuk Lymphoma. 1993. PMID: 8251904 Review. - Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells.
Eaves CJ, Cashman JD, Wolpe SD, Eaves AC. Eaves CJ, et al. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12015-9. doi: 10.1073/pnas.90.24.12015. Proc Natl Acad Sci U S A. 1993. PMID: 8265663 Free PMC article. - Differential manipulation of normal and chronic myeloid leukemia stem cell proliferation in vitro.
Eaves C, Eaves A. Eaves C, et al. Blood Cells. 1994;20(1):83-93; discussion 93-5. Blood Cells. 1994. PMID: 7994064 Review.
Cited by
- Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal.
Pavlovsky C, Vasconcelos Cordoba B, Sanchez MB, Moiraghi B, Varela A, Custidiano R, Fernandez I, Freitas MJ, Ventriglia MV, Bendek G, Mariano R, Mela Osorio MJ, Pavlovsky MA, de Labanca AG, Foncuberta C, Giere I, Vera M, Juni M, Mordoh J, Sanchez Avalos JC, Cueto G, Miranda S, Levy EM, Bianchini M. Pavlovsky C, et al. J Hematol Oncol. 2023 Apr 29;16(1):43. doi: 10.1186/s13045-023-01440-6. J Hematol Oncol. 2023. PMID: 37120577 Free PMC article. - Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.
Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Jiang X, et al. Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12804-9. doi: 10.1073/pnas.96.22.12804. Proc Natl Acad Sci U S A. 1999. PMID: 10536003 Free PMC article. - Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia.
Zhang B, Ho YW, Huang Q, Maeda T, Lin A, Lee SU, Hair A, Holyoake TL, Huettner C, Bhatia R. Zhang B, et al. Cancer Cell. 2012 Apr 17;21(4):577-92. doi: 10.1016/j.ccr.2012.02.018. Cancer Cell. 2012. PMID: 22516264 Free PMC article. - Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia.
Mukaida N, Tanabe Y, Baba T. Mukaida N, et al. Int J Mol Sci. 2017 Aug 22;18(8):1824. doi: 10.3390/ijms18081824. Int J Mol Sci. 2017. PMID: 28829353 Free PMC article. Review. - Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells.
Welner RS, Amabile G, Bararia D, Czibere A, Yang H, Zhang H, Pontes LL, Ye M, Levantini E, Di Ruscio A, Martinelli G, Tenen DG. Welner RS, et al. Cancer Cell. 2015 May 11;27(5):671-81. doi: 10.1016/j.ccell.2015.04.004. Cancer Cell. 2015. PMID: 25965572 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous